Group 1 - The company, Pianzaihuang, has announced its investment in the Zhaoying Huikang Fund, contributing 200 million yuan, which represents 20% of the fund [1] - The investment is part of the company's strategic development plan, aimed at enhancing its competitiveness in the pharmaceutical industry by leveraging professional investment resources [1] - The fund will primarily invest in sectors such as biomedicine, traditional Chinese medicine, medical devices, consumer healthcare, and medical services [1] Group 2 - The Zhaoying Huikang Fund is a component of the "Yuanshan Plan," initiated by Zhangzhou to promote the development of the traditional Chinese medicine industry and facilitate cross-strait integration in healthcare [2] - Pianzaihuang is identified as a key enterprise in the implementation of the "Yuanshan Plan," which includes the establishment of six funds totaling 6 billion yuan [2] - The successful registration of the Zhaoying Huikang Fund marks it as the third fund to complete the process under the Yuanshan medical health fund initiative, with additional funds in progress [2]

Investment Overview - The company, through its wholly-owned subsidiary, is participating in the establishment of the Zhaoying Huikang Fund, contributing 200 million yuan, which represents 20% of the fund [1][2] - The investment is part of the company's strategic development to enhance its core competitiveness while ensuring stable growth in its main business [2] Fund Registration Progress - The Zhaoying Huikang Fund has completed the private investment fund registration process with the China Securities Investment Fund Industry Association and has obtained the Private Investment Fund Registration Certificate [2] - The fund is managed by招商致远资本投资有限公司 and is custodied by招商银行股份有限公司 [2]

雷达财经 文|杨洋 编|李亦辉 在业绩方面，公司2022年至2024年营业收入分别为86.94亿元、100.58亿元和107.88亿元，同比分别增长8.38%、15.69%和7.25%。归母净利润分别为24.72亿 元、27.97亿元和29.77亿元，归母净利润同比增长分别为1.66%、13.15%和6.42%。同期，公司资产负债率分别为19.04%、18.50%和15.40%。 在风险方面，天眼查信息显示，公司自身天眼风险108条，周边天眼风险273条，历史天眼风险4条，预警提醒天眼风险423条。 天眼查资料显示，片仔癀成立于1999年12月28日，注册资本60331.721万人民币，法定代表人林志辉，注册地址为福建省漳州市芗城区琥珀路1号。主营业务 为医药制造业、医药流通业及化妆品业等。 目前，公司董事长为林志辉，董秘为施艺雄，员工人数为2839人，实际控制人为漳州市人民政府国有资产监督管理委员会。 公司参股公司55家，包括福建片仔癀电子商务有限公司、漳州片仔癀投资管理有限公司、福建片仔癀健康科技有限公司、片仔癀电商国际贸易（香港）有限 公司、漳州片仔癀国药堂医药连锁有限公司等。 5月30日，漳州片公告， ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-017 本次投资招盈慧康基金，经公司第七届董事会第二十七次会议以 及第七届监事会第十九次会议审议通过（详见公告2025-005、006号）。 二、对外投资进展 漳州片仔癀药业股份有限公司 关于投资参与招盈慧康基金的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 漳州片仔癀药业股份有限公司（以下简称"公司"）全资子公司 漳州片仔癀投资管理有限公司（以下简称"片仔癀投资"）与招商致 远资本投资有限公司（以下简称"基金管理人"）、漳州市产业股权 投资有限公司、漳州片仔癀资产经营有限公司、漳州市旅游投资集团 有限公司、漳州台商投资区资产运营集团有限公司共同发起设立漳州 台商投资区招盈慧康股权投资合伙企业（有限合伙）（以下简称"招 盈慧康基金"）。其中，片仔癀投资作为有限合伙人以自有资金认缴 出资20,000万元，占招盈慧康基金的比例为20.00%。 本次投资招盈慧康基金，为公司战略发展的前瞻性布局。在保证 公司主营业务稳健发展的前提下，以基金投资 ...

Core Viewpoint - The company, Pianzaihuang Pharmaceutical Co., Ltd., reported a solid performance in 2024, achieving a consolidated revenue of approximately 10.788 billion yuan, a year-on-year increase of 7.25%, and a net profit attributable to shareholders of about 2.977 billion yuan, up 6.42% from the previous year [4][5][6]. Group 1: Meeting Procedures and Governance - The 2024 Annual General Meeting (AGM) will be held on June 20, 2025, at 09:00, at the Zhangzhou Xiangjiang Hotel [3]. - The meeting will include a verification of the identity of attendees, and shareholders will have the right to speak, inquire, and vote [2][3]. - Voting will be conducted by registered ballot, with each share representing one vote [2][3]. Group 2: Business Performance - The company achieved a consolidated revenue of approximately 10.788 billion yuan in 2024, representing a 7.25% increase year-on-year [4]. - The net profit attributable to shareholders was about 2.977 billion yuan, reflecting a 6.42% increase compared to the previous year [4]. - The company paid approximately 14 billion yuan in cash dividends, accounting for 50.04% of the net profit attributable to shareholders [9]. Group 3: Honors and Recognition - The company was recognized as one of the "Top 100 Enterprises in Comprehensive Competitiveness of Traditional Chinese Medicine Industry" and received multiple awards for its brand value and cultural heritage [5][6]. - The company ranked first in the market capitalization of the traditional Chinese medicine industry, with a market value exceeding 120 billion yuan [6]. - The company received various awards, including the "2023 Golden Bull Most Investment Value Award" and "2024 Top 20 ESG Competitiveness in Chinese Pharmaceutical Listed Companies" [6]. Group 4: Research and Development - The company is focusing on enhancing its independent innovation capabilities, with ongoing clinical research on 14 new drug projects [12][13]. - The company has established partnerships with over 10 academicians for collaborative projects, aiming to accelerate technological breakthroughs [13]. - The company is actively involved in national key research projects, enhancing its research capabilities in traditional Chinese medicine [13][14]. Group 5: Future Plans - The company plans to increase its new drug projects and clinical research initiatives, aiming to launch 2-3 new drug projects in the coming year [21]. - The company will focus on expanding its market presence in traditional medicine channels and new consumer markets [21]. - The company aims to enhance its brand visibility through new media and targeted marketing strategies [21].

证券代码：600436 证券简称：片仔癀 公告编号：2025-016 漳州片仔癀药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 至2025 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段， 即 9:15-9:25,9:30-11:30， 无。 非累积投票议案 《公司关于聘任会计师事务所及确定其报酬事项 的议案》 《公司 2024 年度财务决算及 2025 年度财务预算 报告》 《公司 2025 年度董事、监事、高级管理人员薪酬 额度的议案》 本次股东大会还将分别听取各位独立董事《公司 2024 年度独立 董事述职报告》 。 上述议案已经公司第七届董事会第二十八次会议和第七届监事 会第二十次会议审议通过，相关决议公告及文件已按照规定和要求在 上海证券交易所网站（www.sse.com.cn）及公司选定的中国证监会指 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | | | 投票股 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-016 漳州片仔癀药业股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 召开的日期时间：2025 年 6 月 20 日 09 点 00 分 召开地点：漳州市芗城区漳州芗江酒店二楼芝山厅 1 股东大会召开日期：2025年6月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 20 日 至2025 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段，即9:15-9:25,9:30-11:30， 13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日 的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者 ...

股票代码：600436 股票简称：片仔癀 漳州片仔癀药业股份有限公司 2024 年年度股东大会会议材料 福建·漳州 二〇二五年六月二十日 0 漳州片仔癀药业股份有限公司 2024 年年度股东大会会议材料 漳州片仔癀药业股份有限公司 2024 年年度股东大会事项、表决方法说明 各位股东、股东代表： 根据中国证券监督管理委员会《上市公司股东会规则》和《漳州片仔 癀药业股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 公司 2024 年年度股东大会会议事项、投票表决等规定如下： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对，请被核对者给予配合。 二、股东及股东代表应于会议开始前入场；中途入场者，应经会议工作 人员的许可。 三、股东参加股东大会依法享有发言权、质询权、表决权等权利。股东 参加股东大会应认真履行其法定义务，不得侵犯公司和其他股东的合法权 益，不得扰乱股东大会的正常秩序。 四、要求发言的股东，应当按照会议的议程，经会议主持人许可方可发 言。有多名股东同时要求发言时，先举手者发言；不能确定先后时，由主 持人指定发言者。会议进行中只接受股 ...

Group 1 - The Shanghai Composite Index opened high and fluctuated, with the CSI 300 Pharmaceutical and Biotechnology Index reported at 7798.06 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has increased by 4.26% in the past month, 2.71% in the past three months, and 4.75% year-to-date [1] - The CSI 300 Index samples are categorized into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten weights in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (25.23%), WuXi AppTec (16.45%), Pian Zai Huang (6.51%), Yunnan Baiyao (5.3%), Kelun Pharmaceutical (5.04%), East China Pharmaceutical (3.91%), New Horizon (3.59%), Changchun High-tech (3.57%), Shanghai Raist (3.34%), and Fosun Pharmaceutical (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.57% from the Shanghai Stock Exchange and 36.43% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: Chemical drugs (43.24%), Pharmaceutical and Biotechnology services (21.56%), Traditional Chinese medicine (18.83%), and Biological drugs (16.37%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made when the CSI 300 Index samples are modified [2] - Special events affecting sample companies may lead to changes in industry classification and subsequent adjustments to the CSI 300 industry index samples [2]

证券研究报告 | 金融工程 2025 年 05 月 24 日 刚需+出海+历史低位，多重因素凸显制药价值 ——华宝中证制药 ETF 投资价值分析 随着保健意识的提升及国内人口老龄化趋势的发展，药品作为人们生活中的刚 性需求，其市场需求量日益增长。从供给端来看，原研药专利集中到期，创新 药频获出海订单，中药受政策大力扶持，各细分领域药企均迎来发展机遇。时 逢相关标的位于历史的价格低位，药品制造业显示出一定的投资机会。华宝中 证制药 ETF（认购代码：562053.OF）通过紧密跟踪中证制药指数，一键式配 置制药行业优质上市企业，值得投资者关注。 任瞳 S1090519080004 rentong@cmschina.com.cn ❑ 风险提示：本报告仅作为投资参考，基金产品过往业绩并不预示其未来表 现，亦不构成投资收益的保证或投资建议，新发基金无历史业绩可参考。 敬请阅读末页的重要说明 专题报告 ❑ 在新兴市场经济快速发展和各国医疗保障制度的逐渐完整之下，全球医药 市场规模仍旧维持着稳定增长态势。而据统计，我国的人均药品用量仍远 低于世界发达国家水平，国内药品用量的需求增长仍然具有较大的空间。 ❑ 在供给端，各细 ...